Integra Lifesciences Holdings (IART) Receivables - Other (2017 - 2026)

Integra Lifesciences Holdings' Receivables - Other history runs 10 years deep, the most recent figure standing at $6.7 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 30.13% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (up 30.13% YoY), while the FY2025 annual figure was $6.8 million, up 11.36% from the prior year.
• Receivables - Other came in at $6.7 million for Q1 2026 at Integra Lifesciences Holdings, down from $6.8 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $12.2 million in Q1 2022 to a low of $3.5 million in Q2 2025.
• A 5-year average of $7.9 million and a median of $7.5 million in 2024 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other jumped 87.98% in 2022 and tumbled 47.29% in 2025, its largest moves.
• Integra Lifesciences Holdings' Receivables - Other stood at $10.1 million in 2022, then decreased by 8.78% to $9.2 million in 2023, then sank by 33.43% to $6.1 million in 2024, then increased by 11.36% to $6.8 million in 2025, then retreated by 2.75% to $6.7 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $6.7 million, $6.8 million, and $4.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison